El inhibidor selectivo de la ciclooxigenasa-2, etoricoxib,...

El inhibidor selectivo de la ciclooxigenasa-2, etoricoxib, produce menos efectos secundarios gastrointestinales leves que diclofenaco en el tratamiento del dolor crónico articular. Proyecto Multinational Etoricoxib and Diclofenac Arthritis Long Term programme (MEDAL)

Luis Lizán, Silvia Paz
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
14
Year:
2007
DOI:
10.1016/s1134-2072(07)71874-1
File:
PDF, 51 KB
2007
Conversion to is in progress
Conversion to is failed